- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The RNA-Targeted Small Molecules market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global RNA-Targeted Small Molecules market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the RNA-Targeted Small Molecules global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While mRNA Translation Regulation segment is altered to a % CAGR between 2022 and 2028.
Global key companies of RNA-Targeted Small Molecules include Accent Therapeutics, Anima Biotech Inc., Arrakis Pharmaceuticals, Epics Therapeutics, and Expansion Therapeutics, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
RNA-Targeted Small Molecules market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics
Market segment by Application, can be divided into
Hospitals
Laboratories
Phamacy
Market segment by players, this report covers
Accent Therapeutics
Anima Biotech Inc.
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe RNA-Targeted Small Molecules product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of RNA-Targeted Small Molecules, with revenue, gross margin and global market share of RNA-Targeted Small Molecules from 2019 to 2022.
Chapter 3, the RNA-Targeted Small Molecules competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and RNA-Targeted Small Molecules market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe RNA-Targeted Small Molecules research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of RNA-Targeted Small Molecules
1.2 Classification of RNA-Targeted Small Molecules by Type
1.2.1 Overview: Global RNA-Targeted Small Molecules Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global RNA-Targeted Small Molecules Revenue Market Share by Type in 2021
1.2.3 mRNA Translation Regulation
1.2.4 RNA Splicing Modification
1.2.5 Direct RNA Targeting
1.2.6 Indirect RNA Targeting - Epitranscriptomics
1.3 Global RNA-Targeted Small Molecules Market by Application
1.3.1 Overview: Global RNA-Targeted Small Molecules Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Laboratories
1.3.4 Phamacy
1.4 Global RNA-Targeted Small Molecules Market Size & Forecast
1.5 Global RNA-Targeted Small Molecules Market Size and Forecast by Region
1.5.1 Global RNA-Targeted Small Molecules Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global RNA-Targeted Small Molecules Market Size by Region, (2017-2022)
1.5.3 North America RNA-Targeted Small Molecules Market Size and Prospect (2017-2028)
1.5.4 Europe RNA-Targeted Small Molecules Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific RNA-Targeted Small Molecules Market Size and Prospect (2017-2028)
1.5.6 South America RNA-Targeted Small Molecules Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa RNA-Targeted Small Molecules Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 RNA-Targeted Small Molecules Market Drivers
1.6.2 RNA-Targeted Small Molecules Market Restraints
1.6.3 RNA-Targeted Small Molecules Trends Analysis
2 Company Profiles
2.1 Accent Therapeutics
2.1.1 Accent Therapeutics Details
2.1.2 Accent Therapeutics Major Business
2.1.3 Accent Therapeutics RNA-Targeted Small Molecules Product and Solutions
2.1.4 Accent Therapeutics RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Accent Therapeutics Recent Developments and Future Plans
2.2 Anima Biotech Inc.
2.2.1 Anima Biotech Inc. Details
2.2.2 Anima Biotech Inc. Major Business
2.2.3 Anima Biotech Inc. RNA-Targeted Small Molecules Product and Solutions
2.2.4 Anima Biotech Inc. RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Anima Biotech Inc. Recent Developments and Future Plans
2.3 Arrakis Pharmaceuticals
2.3.1 Arrakis Pharmaceuticals Details
2.3.2 Arrakis Pharmaceuticals Major Business
2.3.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product and Solutions
2.3.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Arrakis Pharmaceuticals Recent Developments and Future Plans
2.4 Epics Therapeutics
2.4.1 Epics Therapeutics Details
2.4.2 Epics Therapeutics Major Business
2.4.3 Epics Therapeutics RNA-Targeted Small Molecules Product and Solutions
2.4.4 Epics Therapeutics RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Epics Therapeutics Recent Developments and Future Plans
2.5 Expansion Therapeutics
2.5.1 Expansion Therapeutics Details
2.5.2 Expansion Therapeutics Major Business
2.5.3 Expansion Therapeutics RNA-Targeted Small Molecules Product and Solutions
2.5.4 Expansion Therapeutics RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Expansion Therapeutics Recent Developments and Future Plans
2.6 Gotham Therapeutics
2.6.1 Gotham Therapeutics Details
2.6.2 Gotham Therapeutics Major Business
2.6.3 Gotham Therapeutics RNA-Targeted Small Molecules Product and Solutions
2.6.4 Gotham Therapeutics RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Gotham Therapeutics Recent Developments and Future Plans
2.7 H3 Biomedicine
2.7.1 H3 Biomedicine Details
2.7.2 H3 Biomedicine Major Business
2.7.3 H3 Biomedicine RNA-Targeted Small Molecules Product and Solutions
2.7.4 H3 Biomedicine RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 H3 Biomedicine Recent Developments and Future Plans
2.8 Ribometrix
2.8.1 Ribometrix Details
2.8.2 Ribometrix Major Business
2.8.3 Ribometrix RNA-Targeted Small Molecules Product and Solutions
2.8.4 Ribometrix RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Ribometrix Recent Developments and Future Plans
2.9 Skyhawk Therapeutics
2.9.1 Skyhawk Therapeutics Details
2.9.2 Skyhawk Therapeutics Major Business
2.9.3 Skyhawk Therapeutics RNA-Targeted Small Molecules Product and Solutions
2.9.4 Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Skyhawk Therapeutics Recent Developments and Future Plans
2.10 STORM Therapeutics
2.10.1 STORM Therapeutics Details
2.10.2 STORM Therapeutics Major Business
2.10.3 STORM Therapeutics RNA-Targeted Small Molecules Product and Solutions
2.10.4 STORM Therapeutics RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 STORM Therapeutics Recent Developments and Future Plans
2.11 Twentyeight-Seven Therapeutics
2.11.1 Twentyeight-Seven Therapeutics Details
2.11.2 Twentyeight-Seven Therapeutics Major Business
2.11.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product and Solutions
2.11.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Twentyeight-Seven Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global RNA-Targeted Small Molecules Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 RNA-Targeted Small Molecules Players Market Share in 2021
3.2.2 Top 10 RNA-Targeted Small Molecules Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 RNA-Targeted Small Molecules Players Head Office, Products and Services Provided
3.4 RNA-Targeted Small Molecules Mergers & Acquisitions
3.5 RNA-Targeted Small Molecules New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global RNA-Targeted Small Molecules Revenue and Market Share by Type (2017-2022)
4.2 Global RNA-Targeted Small Molecules Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global RNA-Targeted Small Molecules Revenue Market Share by Application (2017-2022)
5.2 Global RNA-Targeted Small Molecules Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America RNA-Targeted Small Molecules Revenue by Type (2017-2028)
6.2 North America RNA-Targeted Small Molecules Revenue by Application (2017-2028)
6.3 North America RNA-Targeted Small Molecules Market Size by Country
6.3.1 North America RNA-Targeted Small Molecules Revenue by Country (2017-2028)
6.3.2 United States RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
6.3.3 Canada RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
6.3.4 Mexico RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe RNA-Targeted Small Molecules Revenue by Type (2017-2028)
7.2 Europe RNA-Targeted Small Molecules Revenue by Application (2017-2028)
7.3 Europe RNA-Targeted Small Molecules Market Size by Country
7.3.1 Europe RNA-Targeted Small Molecules Revenue by Country (2017-2028)
7.3.2 Germany RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
7.3.3 France RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
7.3.4 United Kingdom RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
7.3.5 Russia RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
7.3.6 Italy RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific RNA-Targeted Small Molecules Revenue by Type (2017-2028)
8.2 Asia-Pacific RNA-Targeted Small Molecules Revenue by Application (2017-2028)
8.3 Asia-Pacific RNA-Targeted Small Molecules Market Size by Region
8.3.1 Asia-Pacific RNA-Targeted Small Molecules Revenue by Region (2017-2028)
8.3.2 China RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
8.3.3 Japan RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
8.3.4 South Korea RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
8.3.5 India RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
8.3.7 Australia RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America RNA-Targeted Small Molecules Revenue by Type (2017-2028)
9.2 South America RNA-Targeted Small Molecules Revenue by Application (2017-2028)
9.3 South America RNA-Targeted Small Molecules Market Size by Country
9.3.1 South America RNA-Targeted Small Molecules Revenue by Country (2017-2028)
9.3.2 Brazil RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
9.3.3 Argentina RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa RNA-Targeted Small Molecules Revenue by Type (2017-2028)
10.2 Middle East & Africa RNA-Targeted Small Molecules Revenue by Application (2017-2028)
10.3 Middle East & Africa RNA-Targeted Small Molecules Market Size by Country
10.3.1 Middle East & Africa RNA-Targeted Small Molecules Revenue by Country (2017-2028)
10.3.2 Turkey RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
10.3.4 UAE RNA-Targeted Small Molecules Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global RNA-Targeted Small Molecules Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global RNA-Targeted Small Molecules Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market RNA-Targeted Small Molecules Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global RNA-Targeted Small Molecules Revenue (USD Million) by Region (2017-2022)
Table 5. Global RNA-Targeted Small Molecules Revenue Market Share by Region (2023-2028)
Table 6. Accent Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Accent Therapeutics Major Business
Table 8. Accent Therapeutics RNA-Targeted Small Molecules Product and Solutions
Table 9. Accent Therapeutics RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Anima Biotech Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Anima Biotech Inc. Major Business
Table 12. Anima Biotech Inc. RNA-Targeted Small Molecules Product and Solutions
Table 13. Anima Biotech Inc. RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Arrakis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Arrakis Pharmaceuticals Major Business
Table 16. Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product and Solutions
Table 17. Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Epics Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. Epics Therapeutics Major Business
Table 20. Epics Therapeutics RNA-Targeted Small Molecules Product and Solutions
Table 21. Epics Therapeutics RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Expansion Therapeutics Corporate Information, Head Office, and Major Competitors
Table 23. Expansion Therapeutics Major Business
Table 24. Expansion Therapeutics RNA-Targeted Small Molecules Product and Solutions
Table 25. Expansion Therapeutics RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Gotham Therapeutics Corporate Information, Head Office, and Major Competitors
Table 27. Gotham Therapeutics Major Business
Table 28. Gotham Therapeutics RNA-Targeted Small Molecules Product and Solutions
Table 29. Gotham Therapeutics RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. H3 Biomedicine Corporate Information, Head Office, and Major Competitors
Table 31. H3 Biomedicine Major Business
Table 32. H3 Biomedicine RNA-Targeted Small Molecules Product and Solutions
Table 33. H3 Biomedicine RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Ribometrix Corporate Information, Head Office, and Major Competitors
Table 35. Ribometrix Major Business
Table 36. Ribometrix RNA-Targeted Small Molecules Product and Solutions
Table 37. Ribometrix RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Skyhawk Therapeutics Corporate Information, Head Office, and Major Competitors
Table 39. Skyhawk Therapeutics Major Business
Table 40. Skyhawk Therapeutics RNA-Targeted Small Molecules Product and Solutions
Table 41. Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. STORM Therapeutics Corporate Information, Head Office, and Major Competitors
Table 43. STORM Therapeutics Major Business
Table 44. STORM Therapeutics RNA-Targeted Small Molecules Product and Solutions
Table 45. STORM Therapeutics RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Twentyeight-Seven Therapeutics Corporate Information, Head Office, and Major Competitors
Table 47. Twentyeight-Seven Therapeutics Major Business
Table 48. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product and Solutions
Table 49. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Global RNA-Targeted Small Molecules Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 51. Global RNA-Targeted Small Molecules Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 52. Breakdown of RNA-Targeted Small Molecules by Company Type (Tier 1, Tier 2 and Tier 3)
Table 53. RNA-Targeted Small Molecules Players Head Office, Products and Services Provided
Table 54. RNA-Targeted Small Molecules Mergers & Acquisitions in the Past Five Years
Table 55. RNA-Targeted Small Molecules New Entrants and Expansion Plans
Table 56. Global RNA-Targeted Small Molecules Revenue (USD Million) by Type (2017-2022)
Table 57. Global RNA-Targeted Small Molecules Revenue Share by Type (2017-2022)
Table 58. Global RNA-Targeted Small Molecules Revenue Forecast by Type (2023-2028)
Table 59. Global RNA-Targeted Small Molecules Revenue by Application (2017-2022)
Table 60. Global RNA-Targeted Small Molecules Revenue Forecast by Application (2023-2028)
Table 61. North America RNA-Targeted Small Molecules Revenue by Type (2017-2022) & (USD Million)
Table 62. North America RNA-Targeted Small Molecules Revenue by Type (2023-2028) & (USD Million)
Table 63. North America RNA-Targeted Small Molecules Revenue by Application (2017-2022) & (USD Million)
Table 64. North America RNA-Targeted Small Molecules Revenue by Application (2023-2028) & (USD Million)
Table 65. North America RNA-Targeted Small Molecules Revenue by Country (2017-2022) & (USD Million)
Table 66. North America RNA-Targeted Small Molecules Revenue by Country (2023-2028) & (USD Million)
Table 67. Europe RNA-Targeted Small Molecules Revenue by Type (2017-2022) & (USD Million)
Table 68. Europe RNA-Targeted Small Molecules Revenue by Type (2023-2028) & (USD Million)
Table 69. Europe RNA-Targeted Small Molecules Revenue by Application (2017-2022) & (USD Million)
Table 70. Europe RNA-Targeted Small Molecules Revenue by Application (2023-2028) & (USD Million)
Table 71. Europe RNA-Targeted Small Molecules Revenue by Country (2017-2022) & (USD Million)
Table 72. Europe RNA-Targeted Small Molecules Revenue by Country (2023-2028) & (USD Million)
Table 73. Asia-Pacific RNA-Targeted Small Molecules Revenue by Type (2017-2022) & (USD Million)
Table 74. Asia-Pacific RNA-Targeted Small Molecules Revenue by Type (2023-2028) & (USD Million)
Table 75. Asia-Pacific RNA-Targeted Small Molecules Revenue by Application (2017-2022) & (USD Million)
Table 76. Asia-Pacific RNA-Targeted Small Molecules Revenue by Application (2023-2028) & (USD Million)
Table 77. Asia-Pacific RNA-Targeted Small Molecules Revenue by Region (2017-2022) & (USD Million)
Table 78. Asia-Pacific RNA-Targeted Small Molecules Revenue by Region (2023-2028) & (USD Million)
Table 79. South America RNA-Targeted Small Molecules Revenue by Type (2017-2022) & (USD Million)
Table 80. South America RNA-Targeted Small Molecules Revenue by Type (2023-2028) & (USD Million)
Table 81. South America RNA-Targeted Small Molecules Revenue by Application (2017-2022) & (USD Million)
Table 82. South America RNA-Targeted Small Molecules Revenue by Application (2023-2028) & (USD Million)
Table 83. South America RNA-Targeted Small Molecules Revenue by Country (2017-2022) & (USD Million)
Table 84. South America RNA-Targeted Small Molecules Revenue by Country (2023-2028) & (USD Million)
Table 85. Middle East & Africa RNA-Targeted Small Molecules Revenue by Type (2017-2022) & (USD Million)
Table 86. Middle East & Africa RNA-Targeted Small Molecules Revenue by Type (2023-2028) & (USD Million)
Table 87. Middle East & Africa RNA-Targeted Small Molecules Revenue by Application (2017-2022) & (USD Million)
Table 88. Middle East & Africa RNA-Targeted Small Molecules Revenue by Application (2023-2028) & (USD Million)
Table 89. Middle East & Africa RNA-Targeted Small Molecules Revenue by Country (2017-2022) & (USD Million)
Table 90. Middle East & Africa RNA-Targeted Small Molecules Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. RNA-Targeted Small Molecules Picture
Figure 2. Global RNA-Targeted Small Molecules Revenue Market Share by Type in 2021
Figure 3. mRNA Translation Regulation
Figure 4. RNA Splicing Modification
Figure 5. Direct RNA Targeting
Figure 6. Indirect RNA Targeting - Epitranscriptomics
Figure 7. RNA-Targeted Small Molecules Revenue Market Share by Application in 2021
Figure 8. Hospitals Picture
Figure 9. Laboratories Picture
Figure 10. Phamacy Picture
Figure 11. Global RNA-Targeted Small Molecules Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global RNA-Targeted Small Molecules Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global RNA-Targeted Small Molecules Revenue Market Share by Region (2017-2028)
Figure 14. Global RNA-Targeted Small Molecules Revenue Market Share by Region in 2021
Figure 15. North America RNA-Targeted Small Molecules Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe RNA-Targeted Small Molecules Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific RNA-Targeted Small Molecules Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America RNA-Targeted Small Molecules Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa RNA-Targeted Small Molecules Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. RNA-Targeted Small Molecules Market Drivers
Figure 21. RNA-Targeted Small Molecules Market Restraints
Figure 22. RNA-Targeted Small Molecules Market Trends
Figure 23. Accent Therapeutics Recent Developments and Future Plans
Figure 24. Anima Biotech Inc. Recent Developments and Future Plans
Figure 25. Arrakis Pharmaceuticals Recent Developments and Future Plans
Figure 26. Epics Therapeutics Recent Developments and Future Plans
Figure 27. Expansion Therapeutics Recent Developments and Future Plans
Figure 28. Gotham Therapeutics Recent Developments and Future Plans
Figure 29. H3 Biomedicine Recent Developments and Future Plans
Figure 30. Ribometrix Recent Developments and Future Plans
Figure 31. Skyhawk Therapeutics Recent Developments and Future Plans
Figure 32. STORM Therapeutics Recent Developments and Future Plans
Figure 33. Twentyeight-Seven Therapeutics Recent Developments and Future Plans
Figure 34. Global RNA-Targeted Small Molecules Revenue Share by Players in 2021
Figure 35. RNA-Targeted Small Molecules Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players RNA-Targeted Small Molecules Revenue Market Share in 2021
Figure 37. Global Top 10 Players RNA-Targeted Small Molecules Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global RNA-Targeted Small Molecules Revenue Share by Type in 2021
Figure 40. Global RNA-Targeted Small Molecules Market Share Forecast by Type (2023-2028)
Figure 41. Global RNA-Targeted Small Molecules Revenue Share by Application in 2021
Figure 42. Global RNA-Targeted Small Molecules Market Share Forecast by Application (2023-2028)
Figure 43. North America RNA-Targeted Small Molecules Sales Market Share by Type (2017-2028)
Figure 44. North America RNA-Targeted Small Molecules Sales Market Share by Application (2017-2028)
Figure 45. North America RNA-Targeted Small Molecules Revenue Market Share by Country (2017-2028)
Figure 46. United States RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe RNA-Targeted Small Molecules Sales Market Share by Type (2017-2028)
Figure 50. Europe RNA-Targeted Small Molecules Sales Market Share by Application (2017-2028)
Figure 51. Europe RNA-Targeted Small Molecules Revenue Market Share by Country (2017-2028)
Figure 52. Germany RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific RNA-Targeted Small Molecules Sales Market Share by Type (2017-2028)
Figure 58. Asia-Pacific RNA-Targeted Small Molecules Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific RNA-Targeted Small Molecules Revenue Market Share by Region (2017-2028)
Figure 60. China RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America RNA-Targeted Small Molecules Sales Market Share by Type (2017-2028)
Figure 67. South America RNA-Targeted Small Molecules Sales Market Share by Application (2017-2028)
Figure 68. South America RNA-Targeted Small Molecules Revenue Market Share by Country (2017-2028)
Figure 69. Brazil RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa RNA-Targeted Small Molecules Sales Market Share by Type (2017-2028)
Figure 72. Middle East and Africa RNA-Targeted Small Molecules Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa RNA-Targeted Small Molecules Revenue Market Share by Country (2017-2028)
Figure 74. Turkey RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE RNA-Targeted Small Molecules Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
